Iradimed Total Current Liabilities vs Non Currrent Assets Other Analysis
IRMD Stock | USD 50.39 0.12 0.24% |
Iradimed financial indicator trend analysis is infinitely more than just investigating Iradimed recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iradimed is a good investment. Please check the relationship between Iradimed Total Current Liabilities and its Non Currrent Assets Other accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Total Current Liabilities vs Non Currrent Assets Other
Total Current Liabilities vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iradimed Total Current Liabilities account and Non Currrent Assets Other. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Iradimed's Total Current Liabilities and Non Currrent Assets Other is 0.96. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Iradimed Co, assuming nothing else is changed. The correlation between historical values of Iradimed's Total Current Liabilities and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Iradimed Co are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Total Current Liabilities i.e., Iradimed's Total Current Liabilities and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.96 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Current Liabilities
Total Current Liabilities is an item on Iradimed balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Iradimed Co are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Iradimed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iradimed current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Iradimed's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 51.10, whereas Selling General Administrative is forecasted to decline to about 9.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 32.0M | 41.3M | 50.2M | 27.1M | Total Revenue | 41.8M | 53.3M | 65.6M | 35.1M |
Iradimed fundamental ratios Correlations
Click cells to compare fundamentals
Iradimed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iradimed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 66.7M | 71.1M | 82.9M | 85.5M | 92.2M | 54.5M | |
Other Current Liab | 3.0M | 2.1M | 3.2M | 3.1M | 11.5M | 12.0M | |
Total Current Liabilities | 5.9M | 4.9M | 6.8M | 8.6M | 16.3M | 17.1M | |
Total Stockholder Equity | 55.5M | 61.4M | 72.2M | 73.7M | 71.4M | 46.1M | |
Other Liab | 2.6M | 2.3M | 1.7M | 1.4M | 1.6M | 1.4M | |
Property Plant And Equipment Net | 5.0M | 4.8M | 4.6M | 2.4M | 11.3M | 11.9M | |
Current Deferred Revenue | 1.7M | 1.9M | 2.6M | 3.4M | 2.6M | 1.7M | |
Net Debt | (40.5M) | (47.4M) | (59.5M) | (55.8M) | (47.7M) | (45.3M) | |
Retained Earnings | 36.3M | 37.7M | 47.0M | 47.3M | 43.3M | 27.5M | |
Accounts Payable | 993.7K | 657.1K | 782.9K | 1.8M | 1.9M | 1.0M | |
Cash | 43.5M | 50.1M | 62.0M | 58.0M | 49.8M | 33.0M | |
Non Current Assets Total | 7.8M | 7.3M | 6.6M | 7.3M | 16.2M | 17.0M | |
Non Currrent Assets Other | 232.0K | 262.0K | 201.3K | 2.2M | 4.8M | 5.1M | |
Other Assets | 1.9M | 6.4M | 966.4K | 1.3M | 1.0 | 0.95 | |
Cash And Short Term Investments | 46.3M | 52.0M | 62.5M | 58.0M | 49.8M | 37.0M | |
Net Receivables | 7.3M | 4.6M | 5.1M | 13.3M | 12.2M | 12.8M | |
Common Stock Total Equity | 1.2K | 1.2K | 1.3K | 1.3K | 1.4K | 1.2K | |
Common Stock Shares Outstanding | 12.3M | 12.4M | 12.6M | 12.6M | 12.7M | 13.0M | |
Short Term Investments | 8.1M | 6.3M | 2.8M | 1.9M | 501.9K | 0.0 | |
Liabilities And Stockholders Equity | 66.7M | 71.1M | 82.9M | 85.5M | 92.2M | 54.5M | |
Non Current Liabilities Total | 5.3M | 4.8M | 3.9M | 3.3M | 4.4M | 2.5M | |
Inventory | 3.6M | 3.9M | 4.3M | 5.4M | 12.8M | 13.5M | |
Other Current Assets | 407.8K | 771.7K | 1.0M | 631.0K | 1.2M | 1.3M | |
Other Stockholder Equity | 19.2M | 23.7M | 25.2M | 26.4M | 28.2M | 18.5M | |
Total Liab | 11.2M | 9.7M | 10.7M | 11.8M | 20.7M | 21.8M | |
Property Plant And Equipment Gross | 5.0M | 4.8M | 4.6M | 8.0M | 15.4M | 16.2M | |
Total Current Assets | 59.0M | 63.7M | 76.2M | 78.2M | 76.0M | 49.0M | |
Accumulated Other Comprehensive Income | (42.2K) | 30.4K | 37.1K | 17.0K | 19.6K | 20.5K | |
Short Term Debt | 240.8K | 255.7K | 276.6K | 293.5K | 428.0K | 355.5K | |
Intangible Assets | 860.1K | 960.9K | 1.1M | 2.1M | 2.5M | 2.6M | |
Common Stock | 1.2K | 1.2K | 1.3K | 1.3K | 1.3K | 1.2K | |
Property Plant Equipment | 2.1M | 2.1M | 4.6M | 2.4M | 2.8M | 1.9M | |
Net Tangible Assets | 54.7M | 60.4M | 71.1M | 71.6M | 82.3M | 50.6M | |
Retained Earnings Total Equity | 36.3M | 37.7M | 47.0M | 47.3M | 54.4M | 30.9M | |
Capital Surpluse | 19.2M | 23.7M | 25.2M | 26.4M | 30.4M | 20.7M | |
Net Invested Capital | 55.5M | 61.4M | 72.2M | 73.7M | 71.4M | 64.3M | |
Net Working Capital | 53.1M | 58.8M | 69.4M | 69.6M | 59.7M | 60.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
V | Visa Class A | |
MSFT | Microsoft |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.152 | Dividend Share 0.3 | Earnings Share 1.46 | Revenue Per Share 5.498 | Quarterly Revenue Growth 0.112 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.